Show simple item record

dc.contributor.authorPURNHAGEN, Kai Peter
dc.identifier.citationFood and Drug Law Journal, 2008, 63, 3, 623-645en
dc.description.abstractPharmaceutical Companies are highly globalized. This widening of drug markets leads to an erosion of the national government‘s legislative powers. With trials and marketing of compounds and pharmaceuticals carried out in different countries, ensuring safety and effectiveness of drugs becomes increasingly problematic. Thus, international pharmaceutical approval harmonization as well as drug monitoring, belongs paramount. One way of solving this problem might be to model an international pharmaceutical authorization system on the European Decentralized Procedure with involvement of the International Conferences of Harmonisation. That’s the focus of this article.en
dc.titleThe Challenge of Globalization in Pharmaceutical Law: Is an International Drug Approval System Modeled after the European System Worth Considering?en

Files associated with this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record